1-5 of 5
Andrej Vranovsky
Close
Sort by
Journal Articles

ASP210 - a Potent Oligonucleotide-Based Inhibitor for Combating Both BCR-ABL1 Dependent and Independent TKI-Resistant CML Cells

Veronika Nemethova, Petra Mazancova, Boglarka Nemethova, Lucia Uhelska, Andrea Babelova, Michal Selc, Kristina Jakic, Ondrej Mitrovsky, Denisa Myslivcova, Marketa Zackova, Alexandra Poturnayova, Angelika Batorova, Antonia Hatalova, Katarina Slezakova, Lubos Drgona, Iveta Oravcova, Eva Mikuskova, Ludmila Demitrovicova, Andrej Vranovsky, Filip Razga
Journal: Blood
Blood (2022) 140 (Supplement 1): 12995–12996.
https://doi.org/10.1182/blood-2022-166148
Published: 2022
Journal Articles

Maintenance Rituximab Every 2 Months for 2 Years Is Effective and Well Tolerated In Patients with Follicular Lymphoma with Both Standard or Rapid Infusion: Updated Results From the Phase IIIb MAXIMA Study

Robin Foá, MD, Alice Di Rocco, Guy van Hazel, Dalton FA Chamone, Klaus Ruffert, Jacob M. Rowe, Luca Arcaini, Irina Poddubnaya, Anthony D. Ho, MD, FRCPC, Valentina Ivanova, Andrej Vranovsky, MD, Mathias Witzens-Harig
Journal: Blood
Blood (2010) 116 (21): 3945.
https://doi.org/10.1182/blood.V116.21.3945.3945
Published: 2010
Journal Articles

BCL-2/IgH PCR Values at the End of Induction Treatment Are Not Predictive for Progression Free Survival in Relapsed/Resistant Follicular Lymphoma: Results of a Prospective Randomized Phase III Intergroup Trial.

Bert A. van der Reijden, PhD, Marinus H.J Van Oers, MD.PhD, Evelyn Tonissen, Martine Van Glabbeke, PhD, Livia Giurgia, Richard Klasa, MD.PhD, Robert E. Marcus, MD.PhD, Max Wolf, MD.PhD, Mars Van t Veer, MD.PhD, Andrej Vranovsky, MD, Harald Holte, MD, Eva Kimby, MD, Anton Hagenbeek, MD.PhD
Journal: Blood
Blood (2007) 110 (11): 791.
https://doi.org/10.1182/blood.V110.11.791.791
Published: 2007
Journal Articles

Rituximab maintenance improves clinical outcome of relapsed/resistant follicular non-Hodgkin lymphoma in patients both with and without rituximab during induction: results of a prospective randomized phase 3 intergroup trial

Clinical Trials & Observations
Marinus H. J. van Oers, Richard Klasa, Robert E. Marcus, Max Wolf, Eva Kimby, Randy D. Gascoyne, Andrew Jack, Mars van't Veer, Andrej Vranovsky, Harald Holte, Martine van Glabbeke, Ivana Teodorovic, Cynthia Rozewicz, Anton Hagenbeek
Journal: Blood
Blood (2006) 108 (10): 3295–3301.
https://doi.org/10.1182/blood-2006-05-021113
Published: 2006
Journal Articles

Four ABVD and Involved-Field Radiotherapy in Unfavorable Supradiaphragmatic Clinical Stages (CS) I-II Hodgkin’s Lymphoma (HL): Preliminary Results of the EORTC-GELA H9-U Trial.

Christophe Ferme, MD, Marine Diviné, MD, Andrej Vranovsky, MD, Frank Morschhauser, MD, Réda Bouabdallah, MD, Jean Gabarre, MD, Aspasia Bastard-Stamatoullas, MD, Richard Delarue, MD, Vittorina Zagonel, MD, Jérôme Jaubert, MD, Anton Hagenbeek, MD, Mark Henri H. Kramer, MD, Chantal Rieux, José Thomas, MD, Michel Henry-Amar, MD
Journal: Blood
Blood (2005) 106 (11): 813.
https://doi.org/10.1182/blood.V106.11.813.813
Published: 2005